Tag Archives: ADC TECHNOLOGY

Conventional anti-cancer therapeutics are characterized by on-target-off-tumor toxicities, which renders them harmful to patients. Such concerns were instrumental in paving the way for targeted therapies. Antibody drug conjugates are a complex and versatile form of anti-cancer therapy, which have been proven to be more effective and less toxic to patients. …

Read More »